GlobeNewswire Clinical StudiesOriginal article
Creative Medical Technology Holdings Successfully Completes Enrollment and Treatment Across Entire FDA-Cleared ADAPT Trial, Including Opioid Cohort, Advancing CELZ-201 / Olastrocel Toward RMAT Evaluation and Phase 3 Planning
Trial StartpositiveCELZ-201 / OlastrocelPositive
AI Analysis
Summary
Creative Medical Technology Holdings completed enrollment and treatment across all cohorts of the FDA-cleared ADAPT trial for CELZ-201/Olastrocel, including an opioid indication expansion cohort, positioning the program toward RMAT evaluation and Phase 3 planning.
Clinical Trial Data
Outcome Details
Enrollment and treatment completed across all FDA-cleared ADAPT trial cohorts including opioid expansion cohort
Importance:6/10
Sentiment:
0.70
clinical trialenrollment completionFDA-cleared trialcell therapyRMAT pathwayPhase 3 planning
Related Companies
Read the original article
Published by GlobeNewswire Clinical Studies on August 20, 2026 1:15 PM